通阳化气方治疗水气凌心型肺心病临床研究  

Clinical study on Tongyang Huaqi Decoction in the treatment of pulmonary heart disease of Shuiqi Lingxin type

作　　者：顾志钰 刘浩恩 庄晓丹[1] GU Zhijue;LIU Haoen;ZHUANG Xiaodan(Department of Traditional Chinese Medicine,Wujin Hospital Affiliated to Jiangsu University,Changzhou213002,China)

机构地区：[1]江苏大学附属武进医院中医科,江苏常州213002

出　　处：《中国现代医生》2022年第15期144-147,共4页China Modern Doctor

摘　　要：目的 探讨通阳化气方治疗水气凌心型肺心病的临床治疗效果。方法 选取2019年1月至2021年3月在江苏大学附属武进医院诊治的水气凌心型肺心病患者92例,采用随机数字表法分为观察组和对照组,每组各46例。对照组给予常规西医治疗,观察组患者在对照组基础上给予通阳化气方。比较两组治疗前和治疗后心功能指标左室射血分数(LVEF)和左室舒张末期内径(LVEDD),并测定N-末端脑钠肽前体(NT-pro BNP),转化生长因子β1(TGF-β1)水平、24 h尿量和日常生活活动(ADL)量表评分。结果 两组治疗前心功能指标比较,差异无统计学意义(P>0.05);经治疗后,两组LVEF相比治疗前均显著升高,LVEDD显著降低(P<0.05),观察组LVEF显著高于对照组[(59.38±6.27)%vs.(55.12±5.30)%],LVEDD显著低于对照组[(43.87±4.68)mm vs.(50.11±5.26)mm](P<0.05);两组治疗前NT-pro BNP和TGF-β1水平比较,差异无统计学意义(P>0.05);经治疗后,两组NT-pro BNP和TGF-β1比较于治疗前均显著降低(P<0.05),观察组NT-pro BNP[(1134.08±77.23)pg/ml vs.(1592.66±73.59)pg/ml]和TGF-β1[(133.37±14.88)pg/ml vs.(178.25±20.17)pg/ml]显著低于对照组(P<0.05);两组治疗前24 h尿量和ADL评分比较,差异无统计学意义(P>0.05);经治疗后,两组24 h尿量和ADL评分比较于治疗前均显著升高(P<0.05),观察组24 h尿量[(1782.53±102.77)ml vs.(1289.20±76.35)ml]和ADL评分[(81.23±7.21)分vs.(74.90±6.22)分]显著高于对照组(P<0.05)。结论 通阳化气方可有效改善水气凌心型肺心病患者的心功能,提高24 h尿量,降低NT-pro BNP和TGF-β1水平。Objective To investigate the clinical therapeutic effect of Tongyang Huaqi Decoction in the treatment of pulmonary heart disease of Shuiqi Lingxin type. Methods From January 2019 to March 2021,a total of 92 patients with pulmonary heart disease of Shuiqi Lingxin type were selected from Wujin Hospital Affiliated to Jiangsu University and divided into the observation group(n=46) and the control group(n=46) by random number method.The patients in the control group were treated with conventional western medicine. The patients in the observation group were given Tongyang Huaqi Decoction based on the treatment in the control group. Cardiac function indicators, including left ventricular ejection fraction(LVEF) and left ventricular end-diastolic diameter(LVEDD), were compared between the two groups before and after treatment. N-terminal pro-brain natriuretic peptide(NT-pro BNP), transforming growth factor β1(TGF-β1) levels,24 h urine volume, and activities of daily living(ADL) scale scores were measured. Results There was no significant difference in cardiac function indicators before treatment between the two groups(P >0.05).After treatment,LVEF was significantly increased, and LVEDD was significantly decreased in both groups compared with before treatment(P <0.05). LVEF was significantly higher in the observation group than in the control group[(59.38±6.27)% vs.(55.12±5.30)%],LVEDD was significantly lower than that of the control group [(43.87±4.68) mm vs.(50.11 ±5.26)mm](P <0.05).There was no significant difference in NT-pro BNP and TGF-β1 levels before treatment between the two groups(P>0.05). After treatment,NT-pro BNP and TGF-β1 in both groups were significantly lower than those before treatment(P<0.05). NT-pro BNP in the observation group [(1134.08±77.23)pg/ml vs.(1592.66±73.59)pg/ml]and TGF-β1[(133.37±14.88) pg/ml vs.(178.25±20.17) pg/ml] was significantly lower than that in the control group(P<0.05). There was no significant difference in the 24-hour urine volume and ADL score before treatment betw

关 键 词：肺心病 水气凌心型 通阳化气方 心功能 

分 类 号：R222[医药卫生—中医基础理论]